Niklas Landberg
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes.
Journal: Nature communications
Published: April 10, 2025
IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation.
Journal: Blood cancer discovery
Published: September 26, 2023
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.
Journal: Blood advances
Published: March 25, 2022
Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy.
Journal: Cancer discovery
Published: April 18, 2021
Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
Journal: Genes, chromosomes & cancer
Published: November 24, 2020
Clonal competition within complex evolutionary hierarchies shapes AML over time.
Journal: Nature communications
Published: March 27, 2019
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells.
Journal: Haematologica
Published: February 26, 2019
Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.
Journal: European journal of haematology
Published: August 28, 2017
Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells.
Journal: PloS one
Published: May 23, 2017
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.
Journal: Haematologica
Published: April 10, 2017
Last Updated: 09/26/2026